Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim <scp>PET</scp>/<scp>CT</scp> is beneficial: a prospective multicentre trial of 355 patients
Eldad J. Dann(Rambam Health Care Campus), Ora Paltiel(Hebrew University of Jerusalem), David Lavie(Hadassah Medical Center), Tamar Tadmor(Bnai Zion Medical Center), Rosa Ruchlemer(Shaare Zedek Medical Center), Kalman Filanovsky(Kaplan Medical Center), Olga Kagna(Girls Incorporated), Abraham Kornberg(Tel Aviv University), Ofer Shpilberg(Texas Oncology), Osnat Bairey(Tel Aviv University), Uri Abadi(Tel Aviv University), Luiza Akria(Western Galilee Hospital), Neta Goldschmidt(National Institutes of Health), Ron Epelbaum(University of Bern), Elinor Barzilai(Rambam Health Care Campus), Tanya Mashiach(Rambam Health Care Campus), Dina Ben‐Yehuda(Hebrew University of Jerusalem), Netanel A. Horowitz(Rambam Health Care Campus), Roxolyana Abdah‐Bortnyak(Mansoura University), Rachel Bar‐Shalom(Rambam Health Care Campus)
Cited by 34
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k